Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3222 - Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: an analysis of adjuvant TOSCA trial


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Immunology

Tumour Site

Colon and Rectal Cancer


Fausto Petrelli


Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281


F. Petrelli1, G. Rosati2, M. Banzi3, M.G. Zampino4, N. Pella5, M. Di Bartolomeo6, E. Maiello7, P. Bidoli8, D. Ferrari9, L. Rimassa10, R. Labianca11, M. Scartozzi12, S. Lonardi13, S. de Placido14, A. Zaniboni15, A. Sobrero16, L.G. Frassineti17, N. Silvestris18, D. Corsi19, F. Galli20, S. Barni21

Author affiliations

  • 1 Oncology, Azienda Ospedaliera Treviglio-Caravaggio, 24047 - Treviglio/IT
  • 2 Oncology, ospedale San Carlo, Potenza/IT
  • 3 Oncology, arcispedale santa maria nuova-IRCCS, reggio emilia/IT
  • 4 Oncology, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 5 Oncology, Azienda Ospedaliero Universitaria Santa Maria della Misericordia, udine/IT
  • 6 Istituto Nazionale Dei Tumori, Fondazione IRCCS, Milan/IT
  • 7 Oncology, Hospital Casa Sollievo della Sofferenza-IRCCS, san giovanni rotondo/IT
  • 8 Oncology, San Gerardo dei Tintori Hospital, monza/IT
  • 9 Oncology, azienda ospedaliera san paolo, milano/IT
  • 10 ., Humanitas Clinical and Research Center, Rozzano/IT
  • 11 Oncology, Azienda Ospedaliera Papa Giovanni XXIII, 24127 - Bergamo/IT
  • 12 Oncology, University Hospital and University of Cagliari, cagliari/IT
  • 13 Oncology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 14 Oncology, AOU Policlinico Federico II, 80131 - Napoli/IT
  • 15 Oncology, casa di cura poliambulanza, brescia/IT
  • 16 Medical Oncology, IRCCS Ospedale San Martino IST, Genoa/IT
  • 17 Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 18 Oncology, Ospedale Oncologico "Giovanni Paolo II"- IRCCS, bari/IT
  • 19 Oncology, Ospedale S.Giovanni Calibita FBF, roma/IT
  • 20 Laboratory Of Clinical research Methodology, IRCCS laboratorio ricerche farmacologiche Mario Negri, milano/IT
  • 21 Oncology, ASST Bergamo Ovest, 24047 - treviglio/IT

Abstract 3222


Prognostic factors in resected colon cancer (CC) guide adjuvant therapy and intensity of follow up. Inflammation parameters as C-reactive protein and neutrophil counts in relation to lymphocyte number (neutrophil/lymphocyte ratio: NLR) have been correlated with poor prognosis in advanced tumors. To confirm the prognostic value of a prechemoterapy NLR in adjuvant setting, we performed a retrospective analysis of high risk stage II and stage III resected CC patients randomized into the TOSCA phase 3 trial comparing 3 or 6 months of adjuvant chemotherapy.


patients randomized in TOSCA trial with data available for NLR analysis before chemotherapy were included. A recursive partitioning analysis was performed to identify the best cut-off that better discriminates patients in terms of relapse-free survival (RFS). According to this cut-off, RFS and overall survival (OS) hazard ratios (HR) for NLR were calculated and adjusted for age, sex, treatment type (XELOX vs FOLFOX) and duration (3 vs 6 months), grade, stage, performance status (PS), site and CEA level.


Out of 3759 subjects randomized in the TOSCA trial, 1590 were included in the efficacy analysis. Mean NLR was 2.1 (median 1.8; range 0.3-24.0). Among patients analysed, 17.4% relapsed and 12.2% died. The best NLR cut off detect in this analysis population is 2.33. However, only age, PS, stage III and CEA levels were associated with RFS and OS in multivariate analysis, but not NLR>2.33 (RFS: HR = 1.17, 95%CI 0.90-1.51; P = 0.24, OS: HR = 1.16 95%CI 0.84-1.61; P = 0.38). Site was also correlated with poor OS.


Prechemotherapy NLR is not significantly associated with poor prognosis in patients with CC undergoing adjuvant chemotherapy. Resection of primary tumor and the associated reduced inflammatory stimulus may explain the lack of correlation with prognosis of NLR. Baseline evaluation, before surgery, likely represents the better timing to collect this information in cancer patients.

Clinical trial identification

Legal entity responsible for the study



Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.